<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml"><!-- InstanceBegin template="/Templates/template.dwt" codeOutsideHTMLIsLocked="false" -->
	<head>
		<meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
		<title>ProteoTech Inc. &mdash; Our History</title>
		<meta name="Description" content="Small molecule approach to treating Systemic AA Amyloidosis disease" />
		<meta name="Keywords" content="small molecule, amyloid deposits, Systemic AA Amyloidosis disease, FDA, Systebryl, National Institute of Health Small Business Innovation Research Grant, SBIR, National Institute of Arthritis and Musculoskeletal and Skin Disease" />
		<meta name="Language" content="English" />
		<meta name="Robots" content="All" />
		<link href="/css/styles.css" rel="stylesheet" type="text/css" media="screen" />
		<link href="/css/print.css" rel="stylesheet" type="text/css" media="print" />
		<!--[if lte IE 6]>
			<link href="/css/lteie6.css" rel="stylesheet" type="text/css" media="screen" />
		<![endif]-->
		<script type="text/javascript" src="/js/p7popmenu-packed.js"></script>
		<script type="text/javascript" src="/js/SpryEffects-packed.js"></script>
		<script type="text/javascript" src="/js/p7vscscripts.js"></script>
		<script type="text/javascript">
			function MM_effectAppearFade(targetElement, duration, from, to, toggle) {
				Spry.Effect.DoFade(targetElement, {duration: duration, from: from, to: to, toggle: toggle});
			}
		</script>
	</head>
	<body onload="P7_initPM(1,0,1,-20,10)">
		<div id="wrapper">
			<div class="contactAppear" id="contactAppear">
				<p><strong><img src="images/logo.gif" width="219" height="57" align="right" class="logo" /></strong></p>
				<p>
					<strong>ProteoTech, Inc</strong>. <br />
					12040 115th Ave., NE<br />
					Kirkland, WAÂ 98034
				</p>
				<p>
					<strong>Office:</strong> (425) 823-0400<br />
					<strong>Fax: </strong>(425) 823-8508<br />
					<strong>E-mail: </strong> <a href="mailto:info@proteotech.com">info@proteotech.com</a>
				</p>
				<p align="right" class="close"><a href="#" onclick="MM_effectAppearFade('contactAppear', 800, 100, 0, false)">Close Window</a></p>
			</div>
			<div id="logoBand">
				<h1 class="logoBox">
					<a href="../index.html" title="ProteoTech, World Leader in Therapeutics and Diagnostics Targeting Amyloid Diseases">
						<img src="../images/logo.gif" alt="" width="219" height="57" border="0" alt="ProteoTech, Inc" />
					</a>
				</h1>
				<div class="taglineBox">
					<h2>A World Leader in Therapeutics Targeting Misfolded Proteins and Amyloid Diseases</h2>
				</div>
			</div>
			<div id="photoBand">
				<div class="mainPhotoBox"><img src="../images/home_photo_temp.gif" width="680" height="205" /></div>
				<div class="sidebarPhotoBox"><img src="../images/blood-cells.jpg" width="214" height="205" /></div>
			</div>
			<div id="contentBox">
				<div id="navBox">
					<ul id="p7PMnav">
						<li><a href="/" title="ProteoTech Home">Home</a></li>
						<li><a href="/about/mission.html" title="About ProteoTech, Inc" class="p7PMtrg">About Us</a>
							<ul>
								<li><a href="/about/mission.html" title="Our Mission">Our Mission</a></li>
								<li><a href="/about/history.html" title="Our History">Our History</a></li>
								<li><a href="/about/targets.html" title="Targeted Markets">Targeted Markets</a></li>
								<li><a href="/about/intellectual.html" title="Intellectual Property">Intellectual Property</a></li>
								<li><a href="/about/leadership_team.html" title="ProteoTech's Leadership Team">Leadership Team</a></li>
							</ul>
						</li>
						<li><a href="/technologies/proteoglycan.html" title="ProteoTech's Technologies" class="p7PMtrg">Our Technologies</a>
							<ul>
								<li><a href="/technologies/proteoglycan.html" title="Amyloid &amp; Proteoglycan Technologies">Amyloid &amp; Proteoglycan Technologies</a></li>
								<li><a href="/technologies/therapeutic_approach.html" title="Therapeutic Approach">Therapeutic Approach</a></li>
								<li><a href="/technologies/alzheimers_small.html" title="Alzheimer's Small Molecule">Alzheimer's - Small Molecule</a></li>
								<li><a href="/technologies/alzheimers_peptide.html" title="Alzheimer's Peptide">Alzheimer's - Peptide</a></li>
								<li><a href="/technologies/parkinsons.html" title="Parkinson's Small Molecule">Parkinson's - Small Molecule</a></li>
								<li><a href="/technologies/systemic.html" title="AL Amyloidosis - Small Molecule">AL Amyloidosis - Small Molecule</a></li>
							</ul>
						</li>
						<li><a href="/pipeline/pipeline_overview.html" title="Pipeline" class="p7PMtrg">Pipeline</a>
							<ul>
								<li><a href="/pipeline/pipeline_overview.html" title="Pipeline Overview">Overview</a></li>
								<li><a href="/pipeline/exebryl.html" title="Exebryl-1"><strong>Exebryl-1<sup>&reg;</sup></strong></a></li>
								<li><a href="/pipeline/pepticlere.html" title="PeptiClere">PeptiClere<sup>&trade;</sup></a></li>
								<li><a href="/pipeline/synuclere.html" title="Synuclere">Synuclere<sup>&trade;</sup></a></li>
								<li><a href="/pipeline/systebryl.html" title="Systebryl">Systebryl<sup>&trade;</sup></a></li>
							</ul>
						</li>
						<li><a href="/news/news_press.html" title="ProteoTech News and Publications" class="p7PMtrg">News/Publications</a>
							<ul>
								<li><a href="/news/news_press.html" title="News/Press Releases">News / Press Releases</a></li>
								<li><a href="/news/scientific_pubs.html" title="Scientific Publications">Scientific Publications</a></li>
							</ul>
						</li>
						<li><a href="/contact.shtml" title="Contact ProteoTech">Contact Us</a></li>
						<!--[if lte IE 6]><style>#p7PMnav a{height:1em;}#p7PMnav li{height:1em;}#p7PMnav ul li{float:left;clear:both;width:100%}</style><![endif]-->
						<!--[if IE 6]><style>#p7PMnav ul li{clear:none;}</style><![endif]-->
						<!--[if IE 7]><style>#p7PMnav a{zoom:100%;}#p7PMnav ul li{float:left;clear:both;width:100%;}</style><![endif]-->
					</ul>
				</div>
				<table width="895" border="0" cellspacing="0" cellpadding="0">
					<tr class="curvy"><td><img src="../images/curves_top.gif" alt="Proteotech" width="895" height="16"/></td></tr>
					<tr>
						<td class="BG_content_fill">
							<div id="column1">
								<h3 align="center"><strong>SYSTEBRYL&trade; FOR THE TREATMENT OF AL (IMMUNOGLOBULIN LIGHT CHAIN) AMYLOIDOSIS</strong></h3>
								<p>ProteoTech is one of a few companies at the forefront of developing disease-modifying small molecule compounds targeted at inhibiting the formation and aggregation of toxic amyloid deposits found throughout the organs in patients with AL (immunoglobulin light chain), TTR (transthyretin), and AA Amyloid diseases.</p>
								<p>AL amyloidosis impacts an estimated 10,000 to 20,000 victims every year by attacking many of the human body's normal functioning organs (primarily heart and kidney) with toxic amyloid deposits. The result of rapid amyloid deposition within heart in these patients results in congestive heart failure and death within 4-6 months of the diagnosis of the disease. There is no effective FDA approved treatment for this disease on the market today.</p>
								<p><a href="/pipeline/systebryl.html">Systebryl</a>&trade; is believed to be the first drug to prevent and reduce AL amyloid deposits in the body (heart and kidney). <a href="/pipeline/systebryl.html">Systebryl</a>&trade; is being developed by ProteoTech as the first drug to reduce and eliminate amyloid deposits in heart (and other organs) in AL amyloid patients. AL amyloidosis is a type of cancer due to plasma cell (bone marrow) abnormalities that leads to insoluble amyloid deposits in heart, kidney and other tissues. Massive AL amyloid deposits in heart leads to a marked thickening of the ventricles and eventual heart failure and death. The median survival time in stage III AL amyloid patients is only 4-6 months from diagnosis. The only treatment at this time is chemotherapy which is not effective in approximately 40% of AL patients.</p>
								<p>Due to the smaller population impacted by AL Amyloidosis, ProteoTech will request Orphan Drug Status from the FDA for its therapeutic compound in development of <a href="/pipeline/systebryl.html">Systebryl</a>&trade;. If granted, ProteoTech will enjoy market exclusivity and added patent protection for its proprietary technologies.</p>
							</div>
							<div id="column2">
								<script src="/js/pageparts/buttons-ourtech.js"></script>
								<br />
								<br />
								<p><img src="../images/systemic_AA.jpg" /></p>
								<p align="center">AL Amyloidosis attacks key organs</p>
								<br />
								<br />
								<p><a href="../pipeline/systebryl.html"><img src="../images/learn_systebryl.jpg" border="0" /></a></p>
							</div>
						</td>
					</tr>
					<tr class="curvy">
						<td><img src="../images/curves_bottom.gif" alt="Proteotech" width="895" height="16" /></td>
					</tr>
				</table>
			</div>
		</div>
		<div id="footerBox">
			<div id="footer">
				<p>Copyright &copy; 2012 ProteoTech, Inc.<br />425.823.0400&nbsp;&nbsp; <a href="mailto:info@proteotech.com">info@proteotech.com</a></p>
			</div>
		</div>
		<script type="text/javascript">
			var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www.");
			document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E"));
			var pageTracker = _gat._getTracker("UA-5988449-1");
			pageTracker._trackPageview();
		</script>
	</body>
</html>
